EDAP TMS S.A. Continues Italian Expansion
Mar 09,2007
<< Back
EDAP TMS S.A. Continues Italian Expansion
EDAP TMS S.A. Continues Italian Expansion
EDAP TMS S.A. Continues Italian ExpansionLyon, France, March 9, 2007 - EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution of a wide portfolio of minimally invasive medical devices primarily for the treatment of urological diseases announced the launch Revenue Per Procedure service at Villa Claudia, a private clinic in Rome. The company anticipates the site will soon transform to a fixed RPP installation once the center is fully converted to Ablatherm-HIFU.
Pr. Francesco Micali, Urologist at the Villa Claudia Clinic, initially treated patients using Ablatherm-HIFU at the Tor Vergata University site in Rome. The Ablatherm-HIFU technology for localized prostate cancer, regarded as the best in the world, as well as compelling patient outcomes in success and quality of life preservation, convinced him to offer services at Villa Claudia. Ablatherm-HIFU is the only prostate cancer HIFU device proven in now more than 10 years of use to provide success on a repeatable basis at centers worldwide without user error, preserve quality of life and offer financially attractive HIFU services to hospitals. Ablatherm-HIFU reports the top outcomes available on HIFU in peer reviewed literature, including multi-center studies, and the lowest occurrence of side effects.
Pr. Micali commented: "We elected for Ablatherm-HIFU as the undisputed leader in HIFU for prostate cancer based on its clinical data, medical journal articles and consistency of success. I have been convinced by the use of Ablatherm-HIFU technology for prostate cancer and its outstanding clinical results when treating at the Tor Vergata University. I am today all the more enthusiastic about this technology as I will be using the new integrated imaging system at the Villa Claudia, thus allowing for a much shorter treatment time, top imaging quality and more tolerable treatment for patients. The technology is the best available in HIFU with careful consideration in developing protocols to ensure proper treatment without creating undue demands on the urologist. Patients are today seeking alternate therapy choices to treat their cancer without sacrificing lifestyle, and Ablatherm clearly addresses this need. Ablatherm-HIFU has a commanding presence in Europe, with strong interest from patients increasing every day."
"EDAP is very pleased to add this private clinic to our outstanding roster of clinical sites who elected Ablatherm-HIFU as the top global technology for prostate cancer HIFU therapy," said Sergio Pontecorvi, General Manager of EDAP's Italian subsidiary. "Villa Claudia joins 18 Italian Ablatherm-HIFU user sites, 11 of which are treating on an RPP basis and who can attest to the excellent outcomes available by Ablatherm therapy, especially in terms of clearly repeatable outcomes without introducing user bias or error as found in other technologies. We are excited to follow Villa Claudia's success in the months ahead as they fully integrate Ablatherm into their urology armamentarium."
Marc Oczachowski, Chief Operating Officer of EDAP, commented, "We are expanding our aggressive marketing program in key European countries initiated in late 2006, strongly supported by direct sales teams in each market. We clearly see our RPP program is best adapted to strongly address physicians and support hospitals and clinics to immediately begin offering therapy with no initial capital cost. EDAP is present to fully assist the first treatments at new RPP user sites with the support of our highly professional Application Specialist team during the training period providing full confidence of success with Ablatherm-HIFU. Based on our strong clinical and technical data, our robotized Ablatherm device is guaranteeing immediate success for these mobile RPP sites."
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
For more information on the Company, contact Magnolia Investor Relations at (972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com .
In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.
What do you think?
Pr. Francesco Micali, Urologist at the Villa Claudia Clinic, initially treated patients using Ablatherm-HIFU at the Tor Vergata University site in Rome. The Ablatherm-HIFU technology for localized prostate cancer, regarded as the best in the world, as well as compelling patient outcomes in success and quality of life preservation, convinced him to offer services at Villa Claudia. Ablatherm-HIFU is the only prostate cancer HIFU device proven in now more than 10 years of use to provide success on a repeatable basis at centers worldwide without user error, preserve quality of life and offer financially attractive HIFU services to hospitals. Ablatherm-HIFU reports the top outcomes available on HIFU in peer reviewed literature, including multi-center studies, and the lowest occurrence of side effects.
Pr. Micali commented: "We elected for Ablatherm-HIFU as the undisputed leader in HIFU for prostate cancer based on its clinical data, medical journal articles and consistency of success. I have been convinced by the use of Ablatherm-HIFU technology for prostate cancer and its outstanding clinical results when treating at the Tor Vergata University. I am today all the more enthusiastic about this technology as I will be using the new integrated imaging system at the Villa Claudia, thus allowing for a much shorter treatment time, top imaging quality and more tolerable treatment for patients. The technology is the best available in HIFU with careful consideration in developing protocols to ensure proper treatment without creating undue demands on the urologist. Patients are today seeking alternate therapy choices to treat their cancer without sacrificing lifestyle, and Ablatherm clearly addresses this need. Ablatherm-HIFU has a commanding presence in Europe, with strong interest from patients increasing every day."
"EDAP is very pleased to add this private clinic to our outstanding roster of clinical sites who elected Ablatherm-HIFU as the top global technology for prostate cancer HIFU therapy," said Sergio Pontecorvi, General Manager of EDAP's Italian subsidiary. "Villa Claudia joins 18 Italian Ablatherm-HIFU user sites, 11 of which are treating on an RPP basis and who can attest to the excellent outcomes available by Ablatherm therapy, especially in terms of clearly repeatable outcomes without introducing user bias or error as found in other technologies. We are excited to follow Villa Claudia's success in the months ahead as they fully integrate Ablatherm into their urology armamentarium."
Marc Oczachowski, Chief Operating Officer of EDAP, commented, "We are expanding our aggressive marketing program in key European countries initiated in late 2006, strongly supported by direct sales teams in each market. We clearly see our RPP program is best adapted to strongly address physicians and support hospitals and clinics to immediately begin offering therapy with no initial capital cost. EDAP is present to fully assist the first treatments at new RPP user sites with the support of our highly professional Application Specialist team during the training period providing full confidence of success with Ablatherm-HIFU. Based on our strong clinical and technical data, our robotized Ablatherm device is guaranteeing immediate success for these mobile RPP sites."
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
For more information on the Company, contact Magnolia Investor Relations at (972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com .
In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.